NasdaqHealth CarePharmaceutical PreparationsNEWTOWN, PA

Traws Pharma, Inc. TRAW

Ask your AI

Estimated market cap $3.86M15.37M shares, shares as of Aug 12, 2026CIK 1130598

Insider trades, 12 mo

1 buy · 0 sells

$998.2K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

40.1% of shares · 9 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in Traws Pharma, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 14, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Traws Pharma, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

1 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Apr 16, 2026. Insiders have two business days to file.

Recent insider trades
Insider	Traded	Type	Value	Since trade
OrbiMed Capital GP VIII LLC 10% owner	Apr 16 Form 4 ↗	Buy	+$998.2K 597,729 sh @ $1.67	-86.8%

All TRAW insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

6.16M shares

34 funds report TRAW. Values checked against market prices.

Funds own 40% of shares (Q2 2026)

34 funds hold the stock.

Q3 2026: 3.1% · 5,560 of ~8,900 funds reported so far

Q2 202518%
Q3 202516%
Q4 202543%
Q1 202636%
Q2 202640%
Q3 2026 (so far)3.1%

Reports for the quarter ending Sep 30, 2026 are still coming in (17 positions so far, against 35 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 12 new, 9 added to, 8 trimmed, 7 exited since Q1 2026.

Top 13F holders
#
1	Orbimed Advisors LLC 13F ↗	1.20M	$1.0M	+98.7%
2	Ally Bridge Group (NY) LLC 13F ↗	786,236	$663.0K	New
3	Adage Capital Partners GP, LLC 13F ↗	730,000	$615.6K	unchanged
4	ADAR1 Capital Management, LLC 13F ↗	597,729	$504.1K	+287.9%
5	Lynx1 Capital Management LP 13F ↗	559,470	$471.8K	+3610.5%
6	Ikarian Capital, LLC 13F ↗	478,142	$403.2K	-29.5%
7	Sphera Funds Management Ltd. 13F ↗	398,486	$336.0K	New
8	Vanguard Capital Management LLC 13F ↗	330,049	$278.2K	+498.0%
9	Jane Street Group, LLC 13F ↗	216,006	$182.2K	+916.9%
10	Alyeska Investment Group, L.P. 13F ↗	164,376	$138.6K	New

Download CSV Every fund that holds TRAW, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Traws Pharma, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Traws Pharma, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2024	11	—	646,363	$3.8M
Q4 2024	18	+7	1.17M	$10.2M
Q1 2025	18	0	1.73M	$4.0M
Q2 2025	19	+1	1.26M	$1.9M
Q3 2025	18	-1	1.30M	$2.4M
Q4 2025	22	+4	3.42M	$3.9M
Q1 2026	28	+6	3.62M	$6.6M
Q2 2026	34	+6	6.16M	$5.2M
Q3 2026	17	-17	471,328	$277.9K

Each point is a quarter-end, from Q3 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (68232V884). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes12 in 12 mo 8-K events2 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials3 active IPO history6 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Traws Pharma, Inc.
Address: 12 PENNS TRAIL, NEWTOWN, PA 18940
Phone: 267-759-3680
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: TRAW (Nasdaq)
Former names: Onconova Therapeutics, Inc. (until 2024); ONCONOVA THERAPEUTICS INC (until 2009)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.251−$0.03 (−11.87%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.2201 · High $0.4101Nov 13, 2026

Aug 13, 2026Low $0.2201 · High $0.626Nov 13, 2026

Nov 13, 2025Low $0.2201 · High $2.82Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.